Precision Medicine

The biological hurdles of treating solid tumors with T-cell therapy are being decoded through new findings linking tumor lesion diameters to the ultimate durability of the patient response. At the current Society for Immunotherapy of Cancer Annual Meeting, researchers presented updated data

Engineering T-cells to recognize multiple antigens allows the treatment to remain effective even if some tumor cells stop expressing one of the targeted markers. For families facing a pediatric Diffuse Midline Glioma (DMG) diagnosis, the news is historically grim, as this aggressive cancer

The development of cyclic peptides like FAP-2286 underscores the potential of fibroblast activation protein as a versatile pan-cancer target for molecular imaging. This approach has catalyzed a movement toward a more nuanced understanding of how radioactive isotopes can be harnessed to identify and

Emerging radionuclides like Terbium-161 provide a multifaceted approach by emitting beta particles alongside Auger and conversion electrons for microscopic precision. This development represents a massive leap forward in the quest to move beyond the era of blunt-force oncology, where treatments

Statistical trends show a dramatic reduction in the number of patients required to prove efficacy when a companion diagnostic is used to identify likely responders. This transformation represents a fundamental restructuring of the cancer drug development landscape in the United States, as evidenced

The Neonatal Fc receptor has emerged as a high-value target in immunology because it plays a critical role in recycling the antibodies that sustain autoimmune activity. This shift toward complex, target-specific medicine is forcing the global pharmaceutical infrastructure to evolve beyond simple